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RÉSUMÉ 
Le syndrome d'ulcère gastrique équin est une maladie complexe qui affecte des chevaux 
, 
adultes. Sa prévalence peut atteindre 90 % chez les chevaux de course. Bien que 
plusieurs théories aient été proposées, la pathophysiologie de ce syndrome demeure 
inconnue. Le rôle de la cyclooxygénase dans la protection de la muqueuse gastrique a' 
été étudié chez plusieurs espèces, mais pas chez le cheval. L'objectif de cette étude était 
de caractériser l'expression de la COX-l et de la COX-2 dans les ulcères gastriques 
équins. Dix échantillons de muqueuse gastrique non glandulaire équine normale et 38 
échantillons de muqueuse ulcérée ont été prélevés post-mortem. Un spécimen de chaque 
échantillon a été analysé par immunohistochimie et un autre par immunobuvardage. Les 
anticorps MF241 et MF243 dirigés contre la COX-l et la COX-2, respectivement, on! 
été utilisés. L'immunoréactivité a été évaluée avec un système de notation de 0 à 3. 
L'expression des isoformes de la cyclooxygénase a été confirmée par 
immunobuvardage. Tous les échantillons de muqueuse normale exprimaient fortement la 
COX-l, alors que 80 % n'exprimaient pas la COX-2. L'expression de COX-l et,COX-2 
était variable dans les échantillons de muqueuses ulcérées. L'expression de la COX-l 
était significativement inférieure tandis que l'expression de la COX-2 était 
significativement supérieure dans la muqueuse gastriq~e ulcérée comparativement à la 
muqueuse normale (p < 0.0001). Une expression plus élevée de COX-2 dans les ulcères 
gastriques du cheval suggère un rôle possible pour cette enzyme dans leur guérison. 
L'utilisation des inhibiteurs COX-2 spécifiques en guise d'agents anti-inflammatoires 
chez les chevaux devrait donc être faite avec prudence. 
Mots clés: Ulcères gastriques, estomac, cyclooxygénase-l, cyclooxygénase-2, cheval. 
v. 
SUMMARY 
The equine gastric ulcer syndrome is a complex disease which affects adult horses. Its 
prevalence can reach up to 90% in racehorses. Although several theories have been 
proposed, the pathophysiology of this syndrome remains unknown. The role of 
cyc1ôoxygenase in the protection of the gastric mucosa has been studied in several 
species, but not in the horse. The objective of this study was to characterize the 
expression of COX-I and COX-2 in equine gastrie ulcers. Ten samples of normal equine 
nonglandular gastrie mueosa and 38 samples of u1cerated mucosa were obtained post-
mortem. One specimen of each sample was analyzed by immunohistoehemistry and 
another one by immunoblot. Antibodies MF241 and MF243 directed against COX-I and 
COX-2, respectively, were used. The immunoreactivity was evaluated by a scoring 
system from 0 to 3. Expression of the cyc100xygenase isoforms was eonfirmed by 
immunoblot. AlI normal mucosalsamples strongly expressed COX-l, whereas 80% did 
not express COX-2. The expression of COX-l and COX-2 varied considerably in the 
ulcerated mueosal samples. COX-I expression was significantly lower while COX-2 
expression was significantly higher in the ulcerated gastric mucosa than in the normal 
mucosa (p<O.OOOI). A greater expression of COX-2 in equine gastric u1cers suggests a 
possible role for this enzyme in their healing. The· use of specifie COX-2 inhibitors as 
anti-infIammatory drugs in the horse should therefore be made cautiously. 
Key words: Gastrie u1cers, stomaeh, eyc1ooxygenase-I, cyc100xygenase-2, horse. 
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INTRODUCTION 
Gastric ulceration is a frequent condition in horses; it has been associated with feeding 
practices, stress and intensive training or exercise. The exact impact of this disease on 
athletic performance has not been assessed; however it is believed that gastric ulceration 
. results in performance decline. Along with medical treatment costs, this loss of 
performance cou Id lead to important economicallosses to racehorse owners. 
Understanding the pathogenesis of equine gastric ulcer syndrome (EGUS), as weIl as the 
major players involved in its healing process, could le ad to a solution to prevent or 
control this disorder. 
Prostaglandins protect the gastric mucosa against injury from noxious agents; they are 
involved with the gastric mucosal defence barrier in numerous ways. Cyclooxygenase 
(COX) is the core enzyme responsible for prostaglandin synthesis, and its role in gastric 
ulceration has been studied in several species. It was suggested that cyclooxygenase-2 
(COX-2), one of the cyclooxygenase isoforms, had an important role to play in ulcer 
healing. In order to examine the potential role of COX-2 in EGUS, it is necessary to 
identify the expression of this enzyme in the gastric mucosa of horses under physiologic 
and ulcerated conditions. Developinga transendoscopic technique for biopsying the 
equine stomach multiple times, in vivo, without danger to the study subject would be a 
wonderful tool for achieving this goal. 
LITERA TURE REVIEW 
Chapter 1 - The Eguine Stomach 
1.1 Anatomy and Histology of the Equine Stomach 
In contrast with the rest of the equine gastro-intestinal system, the stomach, which has a 
volume of 8 to 15 liters, is very small. The entry of the stomach is the cardia; the exit is 
the pylorus (Picavet 2002). Unlike most domestic species, the horse's stomach is lined 
by two different mucosal types, separated by the margo plicatus. The nonglandular or 
squamous mucosa, where ulcers typically form in adult horses, is a stratified epithelium 
that consists of four histological layers and is located in the upper compartment of the 
stomach. The glandular mucosa is found in the stomach's lower compartment and is 
composed of gastric glands and mucus-secreting cells. The first is considered an 
extension of the esophagus and has no glandular structures, while the latter secretes 
mucus, hydrochloric acid (HCI) and pepsinogen (The Equine Gastric Ulcer Council 
1999). 
The nonglandular mucosa' s histologicallayers are the stratum corneum, which is formed 
by several levels of cornified pyknotic cells; the stratum transitionale, with its large 
round nucleated cells; the stratum spinosum, with smaller oblong cells; and the stratum 
basale, which is composed of cells of cuboidal shape (Argenzio 1999). 
The gastric glands of the glandular portion of the equine stomach are composed of six 
cell types, each one releasing a different substance. Parietal cells release HCl; zymogen 
chief cells release pepsinogen; D-cells release somatostatin; mast cells release histamine; 
surface mucus cells secrete mucus and enterochromaffin-like (ECL) cells release 
histamine as well as serotonin (Garner, Flemstrom et al. 1984; The Equine Gastric Ulcer 
Council 1999). 
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1.2 Physiology of the Equine Stomach 
Mature horses' stomachs can secrete 1.5 liters of gastric juice per hour with an acid 
output range between 4 to 60 mmol of HCl hourly (Campbell-Thompson 1989). The 
gastric pH ranges from 1.5 to 7.0, depending on the region where it is measured. The 
dorsal portion of the oesophageal region can reach a neutral pH, while regions close to 
the margo pUcatus present a pH between 3.0 and 6.0 and the region near the pylorus on 
the glandular mucosa has a pH ranging from 1.5 to 4.0 (Murray and Grodinsky 1989) 
(Figure 1). 
1 
NORMAL FILL 
Figure 1: Illustration of the Equine Stomach Fill and Contents pH 
(Merritt 2003). 
Contrary to many species that can adjust hydrochloric acid secretion based on food 
ingestion, acid is continuously secreted in the equine stomach independently of food 
intake (Campbell-Thompson and Merritt 1987; Murray 1997; Merritt 1999; Herdt 2007). 
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This is likely due to the fact that horses are constant grazers and would eat 
uninterruptedly if allowed access to feed 24 ho urs per day (Herdt 2007). Nowadays, 
however, this aspect of equine physiology can play a role in gastric in jury, since horses 
are fed only twice a day, in most regimens, making the squamous lining of their stomach 
prone to acid grievance. 
Through the buffering effects of increased saliva production, feeding helps to increase 
gastric pH (Murray and Schusser 1993). Gastric emptying of a hay meal occurs in 
24 hours, whereas the same process for a liquid meal can be as fast as half an hour 
(Healy, Lawrence et al. 1993). This may be important since roughage meals are 
considered buffers for gastric acidity. This particular aspect of the horse's gastric 
physiology explains why, nowadays, horses that are fed only twice a day can develop 
gastric injuries, especially to the squamous portion of their stomach, due to constant acid 
exposure. In order to avoid injuries or digestion of the gastric mucosa by acidic gastric 
juices, different mechanisms of mucosal defence have evolved between the glandular 
and nonglandular mucosa. 
1.3 Mechanisms of Glandular Mucosal Defence 
Although high concentrations of HCI and pepsin are present in the stomach, injury to the 
glandular gastric mucosa does not often occur due to mucosal barrier protection 
mechanisms (Sjaastad, Hove et al. 2003). Prostaglandin E2 plays an important role in the 
glandular gastric defence system, promoting bicarbonate and 'mucus secretion, 
suppression of HCI secretion, maintenance of intercellular tight gap junctions and 
adequate mucosal blood flow (Miller 1983; The Equine Gastric Ulcer Council 1999). 
Gastric mucosal cells will secrete bicarbonate in response to an increase in acid 
concentration, mechanical irritation and production of endogenous prostaglandin. 
Regardless of the acidic pH of the luminal surface, the adherence of bicarbonate 
generates a neutral pH at the mucosal surface (Murray 1999). Viscous hydrophobic 
mucus secreted by surface mucous cells also adheres to the mucosal surface to pre vent 
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damage from contact with acid and pepsin. Mechanical damage is minimized since the 
mucus acts as a lubricant as weIl (The Equine Gastric Ulcer Council 1999). 
The tight junctions between gastric epithelial cells also prevent hydrogen ions from 
diffusing amid them (Sjaastad, Hove et al. 2003). AIso, adequate mucosal blood flow is 
imperative in order to remove hydrogen ions that have back diffused into the mucosa 
from the lumen and to supply oxygen and nutrients to sustain the high cellular metabolic 
and regenerative activity (Sorbye and Svanes 1994; Wallace 2001; Crawford and Kumar 
2003). 
Epidermal growth factors (EGFs) are also major players of the glandular mucosal 
defence system. They are secreted by the salivary gland and modulate the rapid cell 
turnover within the stomach by the means of deoxyribonucleic acid (DNA) synthesis 
promotion and proliferation of gastric mucosal cells (Jeffrey, Murray et al. 2001). EGFs 
ensure that glandular gastric cells have a life-span as short as 2 to 3 days, allowing 
damaged surface cells to be rep1aced by new ones before any further harm can be done 
to the mucosa (Sjaastad, Hove et al. 2003). EGFs' role is not restricted to epithelial cell 
restitution, since the y also inhibit the secretion of HCI by parietal cells and are involved 
in prostaglandin synthesis (The Equine Gastric Ulcer Council 1999). AlI of the above 
mentioned mechanisms work together in order to protect the glandular gastric mucosa 
from pep sin and acid assault. 
lA Mechanisms of N onglandular Mucosal Defence 
The nonglandular or squamous mucosa is known to have restricted mechanisms of 
. defence. Acid repulsion and intracellular buffering are the most important ones (Murray 
1999; The Equine Gastric Ulcer Council 1999). The squamous epithelium has no mucus-
secreting glands (Herdt 2007), and the lack of alkaline mucus coating on the 
nonglandular epithelium surface is thought to partially explain why this tissue is prone to 
uIcer development. However, recent studies have raised the possibility of the presence of 
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surface mucus on this epithelium (Murray and Mahaffey 1993; Bullimore, Corfield et al. 
2001), although its role or physical properties have not been elucidated to date. 
Another study has proposed that surfactant may exist on the equine nonglandular 
mucosa in the form of osmiophilic phospholipid material and could be an additional 
physical barrier to back .. diffusion of acid where other defence mechanisms are absent 
(Ethell, Hodgson et al. 2000). Because of the paucity of defence mechanisms, the best 
protection of the equine nonglandular mucosa from peptic injury remains its limited 
. exposure to acidic gastric juices. 
Chapter 2 - Gastric Ulcers 
2.1 Equine Gastric Ulcer Syndrome . 
Equine Gastric Ulcer Syndrome or EGUS is a widespread disease complex that affects 
adult horses (Pagan 1997; Picavet 2002). The high prevalence illustrated by different 
authors in active hors es ranges between 40%, in western performance horses (Bertone 
2000), to greater than 90%, in Standardbreds in active race training (Ferrucci, Zucca et 
al. 2003; Roy, Vrins et al. 2005). In adult horses, ulcers are typically formed in the 
squamous mucosa alongside the margo plicatus, nevertheless they can also be found in 
the glandular and pyloric areas (Andrews and Nadeau 1999; Dionne, Vrins et al. 2003; 
Bezdekova, Jahn et al. 2007). Most affected horses are asymptomatic, although sorne 
symptoms may be decreased appetite, weight loss, rough hair coat, loose faeces, 
diminished performance and slight or recurient colic (Murray 1999; The Equine Gastric 
Ulcer Council 1999). The pathogenesis of this syndrome has yet to be elucidated and 
many theories have been proposed which will be discussed further in this chapter. 
In equine practice, the diagnosis of EGUS is routinely made by assessing treatment 
response. Although sorne have been proposed (Q'Conner, Steiner et al. 2004; Hewetson, 
Cohen et al. 2006; Taharaguchi, Nagano et al. 2007), there are no validated laboratory 
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tests available to confirm the diagnosis of equine gastric ulcers to date. The only 
trustworthy method for diagnosing EGUS is therefore gastroscopy. 
The ulceration process of the squamous gastric mucosa follows a complex sequence of 
events. Reddening of the epithelium is the first change observed endoscopically. 
Histologically this change appears as congested capillaries in the lamina propria and 
epithelium. Prolonged contact of the nonglandular mucosa to HCI then leads to 
denudation of epithelial superficial layers. When this injury extends to, the basal 
epithelial cells, erosion occurs. If the erosion deepens into the lamina propria, the lesion 
becomes an ulcer. Most of the time ulcers do not extend to the muscularis mucosa 
(Murray 1994; Murray and Eichom 1996). 
Several grading systems have been used with the intention of evaluating gastric lesion 
severity (MacAllister, Andrews et al. 1997; Andrews, Reinemeyer et al. 2002). Among 
these, the most accepted and used nowadays is the one proposed by the Equine Gastric 
Ulcer Council, which assigns scores from 0 to 4, where 0 corresponds to intact mucosa 
and 4 to broad, deep lesions (The Equine Gastric Ulcer Council 1999; Bell, Kingston et 
al. 2007). 
The purpose of EGUS treatment is to lower stomach acidity in order to provide an 
environ ment where ulcers can heal (Buchanan and Andrews 2003). Although many 
therapeutic regimens have been employed to treat gastric ulcers in horses, it has, been 
shown by many studies that the most efficient agent is the proton ion pump inhibitor, 
omeprazole (The Equine Gastric Ulcer Council 1999; Buchanan and Andrews 2003; 
Orsini, Haddock et al. 2003; Andrews, Frank et al. 2006). 
2.2 Comparative Pathogenesis of Gastric Ulcers 
Ulcers occurnng m the equme gastric squamous mucosa are comparable to gastro-
esophageal reflux disease (GERD) in humans and porcine gastro-esophageal ulcer 
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disease, since, as in the oesophagus, the gastric squamous mucosa lacks developed 
intrinsic mucosal protective factors (The Equine Gastric Ulcer Council 1999; Murray, 
Eichorn et al. 2001). 
GERD is caused by excessive exposure of the esophageal epithelium to refluxed gastric 
contents, and it occurs mainly because of hiatal hernia or lower esophageal sphincter 
incompetence that permit free reflux to occur (Hunt 1999). 
Porcinegastric ulcers occur primarily in the nonglandular portion of the stomach, called 
the pars oesophagea, and result from risk factors including dietary particle size, gastric 
fluidity, feed carbohydrate content, and existence of commensal gastric organisms 
responsible for dietary carbohydrate fermentation. The role of Helicobacter sp. in the 
development of porcine gastric ulcers has yet to be defined (Doster 2000). 
2.3 Pathogenesis of Equine Gastric Ulcer Syndrome 
EGUS results from an imbalance between mucosal aggressive and defensive 
mechanisms (Andrews and Nadeau 1999). Because mucosal protective factors are more 
developed in the glandular than in the squamous mucosa, the mechanisms which cause 
ulceration in each tissue differ. 
Since naturally occurring gastric ulcers in adult horses is the primary topic of this study, 
the pathogenesis of ulcers in the nonglandular region of the stomach will be the main 
focus of this review while the pathogenesis of glandular ulcers will only be reviewed 
briefly. 
In the glandular mucosa, ulcers are mainly attributable to blood flow disruption and 
. decreased secretion of mucus and bicarbonate. Prostaglandin (PG) inhibition may be the 
leading factor to mucosal protective mechanism disorders, and is considered the primary 
cause of equine gastric glandular ulceration. In fact, the mostcommon occurrence of PG 
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inhibition in horses leading to ulceration of the glandular mucosa is the excessive or 
long term administration of non-selective non-steroidal anti-inflammatory drugs su ch as 
phenylbutazone. 
The pathogenesis of ulceration in the nonglandular region of the equine stomach is 
related to the fact that increased exposure to gastric juices quickly overcomes the lirnited 
defence mechanisms. Continuous exposure of the squamous mucosa to acid contents 
leads to loss of the superficial epithelial layers. The severity of the lesions is associated 
with the duration of exposure to acidity (Furr, Murray et al. 1992), hence the importance 
of identifying the risk factors associated with EGUS. 
It was initially thought that horses confined to stalls have a higher risk of developing 
EGUS than those maintained at pasture because they are more prone to stress and less 
likely to feed constantly (Murray and Eichom 1996; Orsini and Pi pers 1997), however 
recent studies in active racehorses and broodmares that were kept at pasture showed . 
similar EGUS prevalence to horses stabled full time (Bell, Kingston et al. 2007; le 
Jeune, Nieto et al. 2008). Therefore, it appears that pasture tumout alone is insufficient 
protection against gastric ulceration. 
Despite the results reported in two papers (Vatistas, Snyder et al. 1999; Rabuffo, Orsini 
et al. 2002), most studies support that sex and age do not seem to influence EGUS 
prevalence (Murray, Schusser et al. 1996; Roy, Vrins et al. 2005; Bell, Kingston et al. 
2007; Bezdekova, Jahn et al. 2007). 
Prolonged fast has also been shown to cause severe ulceration of the gastric squamous 
epithelial mucosa, triggered by excess acidity (Murray and Eichom 1996). Suppression 
of gastric acidity by ranitidine efficiently reduced the area of ulceration caused by feed 
deprivation (Murray and Eichom 1996). 
The type of feed may also influence the incidence of EGUS. Horses fed alfafa hay or 
alfafa hay and grain had significantly higher gastric juice pH and lower gastric ulcer 
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scores than horses fed bromegrass hay (Nadeau, Andrews et al. 1998; Nadeau, Andrews 
et al. 2000). Because gastric acid output significantly decreased, when corn oil was 
administered to ponies (Cargile, Burrow et al. 2004), it has been hypothesized that 
dietary oils cou Id prevent equine gastric ulceration. However Frank and colleagues 
assessed the antiulcerogenic properties of 3 dietary oils and could not confirm this 
hypothesis (Frank, Andrews et al. 2005). Understanding the difference between gastric 
acid outpùt and pH is fundamental to interpret these findings, because the decrease of 
acid output will only affect the pH of gastric fluid when the OJ.ltput becomes minimal 
(The Equine Gastric Ulcer Council 1999). 
A recent in-vitro study suggested that hydrogen ions cause an increase in outer barrier 
perme ab ility of the nonglandular gastric mucosa, allowing diffusion into the deeper 
sodium-transporting cell layers, which become acidified causing a decrease in sodium 
transport and ultimately cell swelling (Andrews, Buchanan et al. 2008). The same study 
showed that lactated Ringer solution did not alter the bioelectric properties of equine 
nonglandular mucosa, contradicting previous reports where tissue sodium transport and 
resistance were decreased after exposure to volatile fatty acids (Nadeau, Andrews et al. 
2003; Nadeau, Andrews et al. 2003; Andrews, Buchanan et al. 2006). 
Helicobacter pylori infections are associated with most peptic ulcers in humans (Gisbert, 
Calvet et al. 2007; Wilschanski, Schlesinger et al. 2007; Caetano, Felix et al. 2008). 
Helicobacter-like DNA was detected in the healthy and ulcerated gastric mucosa of 
horses (Contreras, Morales et al. 2007), however the pathogenic potential of this finding 
has yet to be assessed. 
Exercise has long been linked to gastric ulceration in several clinical prevalence studies 
(Murray, Schusser et al. 1996; Vatistas, Sifferman et al. 1999; Vatistas; Snyder et al. 
1999; Dionne, Vrins et al. 2003; Roy, Vrins et al. 2005; Bell, Kingston et al. 2007), and 
more specifically exercise intensity was shown to be a significant risk factor in 
Standardbred hors es (Roy, Vrins et al. 2005). Furthermore, it was found that horses 
exercised on a treadmill had increased intra gastric pressure and decreased gastric juice 
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pH as soon as gait passed from walk to trot and from trot to gallop (Lorenzo-Figueras 
and Merritt 2002). Based on these findings, it was hypothesized that when horses move 
in faster gaits abdominal muscles tense and consequently abdominal pressure increases.: 
The increased pressure pushes gastric contents higher than thelr normal fill and places 
the nonglandular mucosa in contact with acidic content. 
Conversely, a recent study demonstrated that there was no difference between pregnant 
and non-pregnant mares with regards to the presence, location and severity of gastric 
ulcers (le Jeune, Nieto et al. 2008). Abdominal pressure has not yet been measured in 
pregnant mares. 
To date, most of the studies investigated general EGUS pathogenesis, however 
information is lacking concerning the molecular pathophysiology of this syndrome, and 
the roles played by different enzymes. 
Chapter 3 - Cyclooxygenase 
3.1 Cyclooxygenase Isoforms 
Prostaglandins (PG) are derivatives of arachidonic acid (AA), a 20-carbon unsaturated 
fatty acid produced from membrane phospholipids (Smith 1989). The principal 
pathways of AA metabolism are 1) the lipoxygenase pathway that results in production 
of leukotrienes (LT), and 2) the cyc100xygenase (COX) pathway, which produces two 
short lived intermediates: prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2) (Smith, 
Marnett et al. 1991). The latter is a substrate for two enzymatic pathways: one that 
results in production of several prostaglandins and another leading to the production of 
thromboxanes (TX). COX is composed of two active sites: a heme with peroxidase 
activity, responsible for the reduction of PGG2 to PGH2, and a cyclooxygenase site, 
where AA is converted into the hydroperoxy endoperoxide PGG2 (van der Ouderaa, 
Buytenhek et al. 1979). The reaction acts through hydrogen atom abstraction from AA 
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by tyrosine radical generated by the peroxidase active site. Two oxygen (02) molecules 
then react with the AA, yielding PGG2 (Figure 2). 
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Figure 2: Representation of COX Activity 
Currently three isoenzymes of cyclooxygenase have been identified: COX-l, COX-2, 
and COX-3 (DuBois, Radhika et al. 1996; Shaftel, Olschowka et al. 2003). COX-1 is 
constitutively expressed, found in most mammalian cells and is associated with 
maintenance of essential physiological functions such as gastric mucosal integrity, renal 
function and platelet homeostasis. COX-2 is responsible for production of PG that 
.occurs during inflammatory processes and is upregulated during the inflammatory 
response and in various carcinomas, playing a role in carcinogenesis (Lee, Soyoola et al. 
1992; Xie, Robertson et al. 1992; Meade, Smith et al. 1993; Mitchell, Akarasereenont et 
al. 1993; O'Sullivan, Huggins et al. 1993; Eberhart, Coffey et al. 1994; DuBois, Radhika 
et al. 1996). Un der normal conditions, COX-2 is constitutively expressed to a 1esser 
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extent in brain, kidney, female reproductive system and bones (Seibert, Zhang et al. 
1997; Miller 2006). During an inflammatory response, inducible COX-2 becomes 
abundant in activated macrophages and other cells at the site of inflammation (Mitchell, 
Akarasereenont et al. 1993; Masferrer and Seibert 1994; Crofford 1997). Different 
tissues express varying levels of COX-l and COX-2. Finally, the third form of COX, 
termed COX-3, is a splicevariant of COX-l that retains intron one and has a frameshift 
mutation; sorne authors refer to it as COX-lb or COX-l variant (COX-Iv) (Shaftel, 
Olschowka et al. 2003). Its exact functions have yet to be determined (Shaftel, 
Olschowka et al. 2003). 
3.2 COX-l and COX-2 Expression in the Gastrointestinal Tract 
In the gastrointestinal tract (GIT), COX -1 is the predominant isoform and has been 
found in the gastric fundus, corpus antrum, and/or pylorus, duodenum, jejunum, ileum, 
cecum, and colon. COX-l is normally expressed in rodents, dogs, humans, and primates 
whereas COX-2 is nearly absent in the se species with low levels detected in the large 
intestine (Kargman, Charleson et al. 1996; Seibert, Zhang et al. 1997; Meyer-Kirchrath 
and Schror 2000; Koki, Khan et al. 2002). 
COX-l is also present in the mucosal epithelium, vascular endothelium, and in smooth 
muscle cells of the tunica muscularis. However, a wide intra-anatomical and interspecies 
variability of COX-l expression levels is present in the GIT. In horses, COX-l protein 
was expressed in ischemic-injured and non-ischemic tissues (Tornlinson, Wilder et al. 
2004). In dogs, protein levels of COX-l are lO-fold higher in the gastric antrum and/or 
pyloric region when compared to the small intestine (Seibert, Zhang et al. 1997). The 
primate small intestine contains five-fold more COX-l protein th an rodent or canine 
small intestinal tissues (Kargman, Charleson et al. 1996) and rodents express lower 
levels of COX-l in the GIT than primates or huinans. In humans, the highest area of 
COX-l expression is in the small intestine and the lowest is in the gastric fundus/antrum 
(Kargman, Charleson et al. 1996). Another study demonstrated strong COX-l and 
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COX-2 immunoreactivity in parietal cells of normal human gastric mucosa (Jackson, 
Wu et al. 2000). 
, 
Expression of COX-l and COX-2 was observed in horses where both isoenzymes were 
expressed in non-ischemic- and ischemic-injured jejunal mucosal tissues. Ischemia was 
found to induce significant upregulation of both isoforms (Tomlinson, Wilder et al. 
2004). Normally, COX-2 is absent from the intestinal tract in ·dogs, non-human primates, 
and humans, except in the colonic mucosa (Koki, Khan et al. 2002). Inflammation of 
GIT induces COX-2 expression and its inhibition by NSAIDs has been shown to delay 
recovery of gastrointestinal (GI) injury in rats (Kishimoto, Wada et al. 1998). In a rat 
model of ischemia-reperfusion-induced acute gastric mucosal injury, an increase in 
COX-2 expression was maximally observed at 24 hours (Kishimoto, Wada et al. 1998). 
The inflamed GI mucosa-mediated COX-2 expression may also affect the chloride and 
fluid flux, both GI secretory responses to infection by bacteria (Eckmann, Stenson et al. 
1997). Greater immunostaining of COX-l and COX-2 was found at the rim of ulcers 
and in Helicobacter pylori gastritis in humans, more specifically at the mid-glandular 
zone and lamina propria inflammatory cells (Jackson, Wu et al. 2000). In humans, 
increased COX-2 has also been found in various hyperplastic and neoplastic Iesions of 
GIT inc1uding colon cancer, familial adenomatous polyposis, and sporadic adenomatous 
polyps in the colon (Soslow, Dannenberg et al. 2000; Khan, Masferrer et al. 2001; Koki, 
Khan et al. 2002). 
In summary, COX-l is considered to be the predominant isoform in the normal GIT 
while COX-2 does not appear to be present in normal GIT of most species studied to 
date. Significant interspecies differences in both the level of COX-l expression and the 
ratio of COX-l and COX-2 expression in the GIT have been observed. Dogs and rats 
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have higher COX-l and COX-lICOX-2 ratio expression than humans and non-human 
primates, which may in part explain the sensitivity of these species to sub-therapeutic 
doses of NSAIDs. As described further in this chapter, in horses, both COX-I and 
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COX-2 proteins were expressed in ischemic-injured and non-ischemic tissues 
(Tomlinson, Wilder et al. 2004). 
3.3 Role of COX-1 and COX-2 in Gastric Mucosal Defence System 
As described previously, a complex protection system exists in the gastric mucosa to 
strengthen its resistance to in jury. Prostaglandins play a crucial role in this system. In 
the GIT, maintenance of mucosal integrity was initially attributed exc1usively to COX-1 
isoform with no contribution of COX-2 (Vane and Botting 1995). Induction of COX-2 
was associated with pathophysiological reactions such as inflammation. Recently, 
studies have shown that COX-2 may also have regulatory functions under physiological 
conditions (Robertson 1998; McAdam, Catella-Lawson et al. 1999). These observations 
indicate that both COX-1 and COX-2 either alone orin concert contribute to gastric 
mucosal integrity. 
Specific inhibition of COX -1 in normal rat glandular gastric mucosa did not induce 
mucosallesions (Wallace, McKnight et al. 2000; Gretzer, Maricic et al. 2001). Selective 
COX-2 inhibitors also did not injure the gastric mucosa when administered alone; 
however, combination with a COX-1 inhibitor resulted in severe gastric damage. Recent 
findings also showed an induction of gastric mucosal injury after combined treatment 
with SC-560 (a specific COX-1 inhibitor) and the COX-2 inhibitor celecoxib but not 
SC-560 alone (Wallace, McKnight et al. 2000). Aiso SC-560 but not celecoxib induced 
reduction in gastric mucosal blood flow and celecoxib but not SC-560 increased 
leukocyte adherence in mesenteric venules suggesting that the two COX isoforms differ 
in their biological activity. COX-1 deficient mice presented no gastric lesions and lower 
gastric PGE2 levels « 1 %) compared to wild type mice (Langenbach, Morham et aL 
1995). Lack of ulcerogenicity was also observed in COX-2 deficient mice (Morham, 
Langenbach et aI: 1995). As previously described, selective pharmacological 
suppression of each COX isoform did not induce damage to the glandular gastric 
mucosa. 
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In contrast to normal glandular gastric mucosa that requires inhibition of both isoforms 
for u1cerogenic lesions to occur, in the acid-challenged rat stomach, inhibition of COX-1 
alone resulted in injury which was further increased by addition of a COX-2 inhibitor or 
prevention of COX-2 up-regulation by dexamethasone (Gretzer, Marieic et al. 2001). 
However, specifie inhibition of COX-2 with rofecoxib and DFU (5,5-dimethyl-3-(3-
fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furan one) in rat mucosa after acid 
challenge did not induce lesions (Gretzer, Maricic et al. 2001). In normal glandular 
gastric mucosa, COX-1 rnRNA expression is high and COX-2 mRNA low but COX-2 
rnRNA was substantially up-regulated after intragastric acid challenge with no effect on 
COX -1 expression (Kargman, Charleson et al. 1996; Maricic, Ehrlich et al. 1999; 
Gretzer, Maricic et al. 2001). Acid-induced up-regulation of COX-2 mRNA was 
prevented by pretreatment with dexamethasone· without alteration in COX-1 rnRNA 
(Gretzer, Maricic et al. 2001). 
Various mediators also act in concert to increase mucosal resistance against in jury. 
Prostaglandins, nitric oxide (NO) and afferent nerves are sorne members of the glandular 
gastric defence system (Whittle, Lopez-Be1monte et al. 1990). As desèribed before, 
inhibition of COX-2 alone did not induce gastric damage even in the presence of acid-
challenge (Gretzer, Maricic et al. 2001). However, association of COX-2 inhibitors 
DFU or NS-398 with a NO inhibitor L-NAME resulted in severe and dose-dependent 
injury in acid-challenged mucosa (Maricic, Ehrlich et al. 1999). Combination of a 
COX-2 inhibitor with capsaicin, a neurotoxie drug, which blocks afferent neurons, 
caused gastric damage even without suppression of NO. These findings indicate that . 
when NO formation or afferent nerves are suppressed, inhibition of COX-2 alone causes 
severe gastric damage in glandular mucosa. 
Finally, in rats, ischemia-reperfusion damage resulted in increased mRNA levels of 
COX-2 in a time-dependent manner without an effect on COX-1 mRNA expression 
(Kishimoto, Wada et al. 1998; Maricic, Ehrlich et al. 1999). The up-regulation of COX-
2 was attenuated after pre-treatment with dexamethasone during ischemia with 
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subsequent reperfusion but had no effect on COX -1 expression (Maricic, Ehrlich et al. 
1999). In rats, occlusion of the gastric artery for 30 min followed by reperfusion for 60 
min resulted in minor gastric in jury. The injury was aggravated up to four-foId after 
treatment with COX-2 inhibitors or dexamethasone and prevented by concurrent 
administration of 16, 16-dimethyl-PGE2 (Peskar, Maricic et al. 2001). The COX-1 
inhibitor also resulted in gastric mucosal in jury. These results suggest that both COX-1 
and COX-2 act to reduce ischemia-reperfusion gastric damage and COX-2 may play a 
more important role in this condition in the glandular mucosa. 
Thesè findings demonstrate that the role of COX isoforms in glandular gastric mucosa 
protection differs in normal mucosa and in mucosa exposed to noxious agents. A 
combination of COX-1 and COX-2 inhibitors is necessary to indu ce injury in normal 
glandular mucosa while in the presence of noxious agents, isolated inhibition of COX-1 
is sufficient to result in mue osaI in jury with increased expression of COX-2. It is 
unknown if these mechanisms of mucosal injury would be the same in nonglandular type 
mucosa. The implications of COX-1.and COX-2 in the nonglandular mucosal defence 
have yet to be elucidated. In naturally occurring nonglandular porcine gastric ulcers, 
COX-2 was strongly expressed (80%) (Lajoie, Sirois et al. 2002). In rats, COX-1 rnRNA 
and protein levels were unaltered while COX-2 mRNA and protein levels were 
increased 2.5-fold and threefold, respectively, in esophageal ulceration when compared 
to normal nonglandular esophageal tissue (Baatar, Jones et al. 2002). The same study 
showed that treatment with celecoxib, a selective COX-2 inhibitor, significantly delays 
esophageal ulcer healing. This finding suggests that COX-2 may play a role in 
nonglandular ulcer healing. 
3.4 Cyclooxygenase and Ulcer Healing 
Ulcer healing is a multifarious process involving cell migration, proliferation, re-
epithelialization, angiogenesis and matrix deposition (Figure 3). AlI of these events lead 
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to scar formation and are controlled by growth factors, transcription factors and 
cytokines (Tamawski 1993; Tamawski 2000; Wong, Playford et al. 2000; Vanwijck 
2001). 
Healing of gastric ulcer 
Figure 3: Illustration of the Ulcer Healing Complex Process 
(Tamawski 2005). 
Cyclooxygenases have also been shown to be involved in ulcer healing. COX-2 mRNA 
and protein were increased in gastric ulcers induced by subserosal injection of acetic 
acid in mice (Mizuno, Sakamoto et al. 1997) while no effect on COX-I mRNA 
expression was observed in ulcerated or non-ulcerated mucosa. However, a threefold 
increase in prostaglandins (PGA2, PGE2, PGF2a) was demonstrated in ulcerated tissue 
when compared to normal tissue and was inhibited by exposure to the COX-2 inhibitor 
NS-398 (Mizuno, Sakamoto et al. 1997). In rats with chronic ulcers, the 
immunoreactivity of COX-2 was low in normal gastric wall and increased during the 
initial phase of ulceration up to day 5, in the tissue of the ulcer base (Schmassmann, 
Peskar et al. 1998). Immunoreactivity of COX-l was located mainly in the non-ulcerated 
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mucosa and was reduced after gastric ulceration in the mucosa adjacent to the ulcer 
crater. COX-l immunoreactivity reappeared from day 5 onwards in the apical 
cytoplasm of the regenerative epithelial cells. These observations demonstrated that, in 
glandular chronic ulcers, COX-l and COX-2 exhibit different spatial and temporal 
patterns of expression. COX-2 is up-regulated in chronic glandular gastric ulcers and 
COX-2 inhibitors prevent the healing of ulcers, indicating that COX-2 plays an 
important roIe in acceleration of u1cer healing. NSAIDs which inhibit both COX-l and 
COX-2 are known to impair the ulcer healing process. Daily administration of 
indomethacin and diclofenac to rats with cryoulcers (ulcers experimentally induced by 
applying a stainless-steel probe cooIed in liquid nitrogen on the surface of the gastric 
mucosa) for 8 or 15 days resulted in a dose-dependent delay in gastric healing 
(Schmassmann, Peskar et al. 1998). Delayed ulcer healing was also observed after daily 
administration of the COX-2 inhibitor L-745,337 in rats. Nonetheless, the role of COX-l 
in gastric ulcer healing remains to be elucidated. Gastric u1cer healing is associated with 
an increase in blood flow (Hirose, Takeuchi et al. 1991). As previously described, 
inhibition of COX-l caused a decrease' in gastric mucosal blood flow (Wallace, 
McKnight et al. 2000), suggesting a possible mechanism by which selective COX-l 
inhibitors impair the healing process. 
The development of COX-l and COX-2knockout mice and selective COX-l and COX-
2 inhibitors allowed to evaluate the role of COX-l and COX-2 in ulcer healing. Wild-
type COX-l knockout (COX-lolo) and COX-2 knockout (COX_2olo) mice with gastric 
ulcers were treated with selective COX-l (SC-560),COX-2 (celecoxib, rofecoxib, and 
valdedoxib) and non-selective COX (piroxicam) inhibitors (Schmassmann, Zoidl et al. 
2006). Healing was moderately impaired by COX-2 gene disruption and COX-2 
inhibitors. Severe healing impairment was observed in dual (SC-560 + rofecoxib) and 
unselective (piroxicam) COX inhibition and combined COX impairment (in COX-lolo 
mice with COX-2 inhibition and COX-2-/- mice with COX-l inhibition). Inhibition of 
COX -1 or gene expression had no effect on ulcer healing. These data suggested that 
COX-2 is an important mediator in ulcer healing and that COX-l becomes important 
when COX-2 is impaired. 
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Vlcer healing also entails local expression of growth factors in the ulcer area, for 
instance, EGF, transforming growth factor (TGFa), hepatocyte growth factor (HGF) and 
basic fibroblast growth factor (bFGF), as weIl as gastrin (Brzozowski, Konturek et al. 
2001). These are expressed at the ulcer margin during ulcer healing (Konturek, 
Brzozowski et al. 1997), which concur with hypergastrinemia, the inhibition of gastric 
acid secretion and increase of mucosal blood flow (Konturek 1990). Gastrin 
administration increases gastric acid secretion and converse1y accelerates ulcer healing, 
showing that healing and gastric acid secretion effects are unrelated with regards to this 
hormone. Moreover, gastrin receptors were found in the regenerative mucosal ulcer 
margin (Schmassmann and Reubi 2000), emphasizing the theory that gastrin contributes 
to mucosal cell proliferation at the ulcer margin (Li and Helander 1996). Local 
application of antibodies against growth factors or gastrin abrogates the acceleration of 
ulcer healing (Brzozowski, Konturek et al. 200 1), showing the specificity of the healing 
promotion of those substances through stimulation of mucosal growth and angiogenesis 
at the ulcer margin. COX-2 gene expression was raised in the ulcerated mucosa after 
treatment with growth factors while COX-1 was unaffected (Brzozowski, Konturek et al. 
2000). Since COX-I and COX-2 inhibitors delay ulcer healing mediated by growth 
factors and upregulation of COX-2 is reflected at the u1cer margin, it can be concluded 
that PGs resulting from the COX-2 pathway mediate u1cer healing via diverse growth 
factors expressed at the ulcer margin. 
3.5 The Role of Cyclooxygenases in Equine Gastrointestinal Tract 
Few studies to date have investigated the role of COX in the equine GIT. One study 
demonstrated that experimentally-induced ischemia increased the passage of 
lipopolysaccarides (LPS) across the equine jejunal mucosa in vitro and that flunixin 
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caused a delay in mucosal recovery without an increase on LPS absorption (Tomlinson 
and Blikslager 2004). Another study showed that permeability of ischemic-injured 
equine jejunum was increased after treatment with flunixin and addition of misoprostol 
(a PGE j analogue) and that treatment with deracoxib (a selective COX-2 inhibitor) 
improved the negative gastrointestinal effects of NSAIDs on the recovery of equine 
intestinal mucosa (Tomlinson and Blikslager 2005). Similar results were found after 
treatment with flunixin or etodolac during ischemia-induced jejunal mucosal injury 
(Tomlinson, Wilder et al. 2004). Both drugs delayed recovery of intestinal barrier 
function after 18 hours of reperfusion and ischemia, and caused an increase in 
expression of COX-l and COX-2 in equine jejunal mucosa. The effects of non-selective 
COX inhibitors (indomethacin and flunixin meglumine) and selective COX-l (SC-560) 
or COX-2 (celecoxib, DUP-398 and NS-697) inhibitors on horse small bowel motility in 
vitro have been investigated (Menozzi, Pozzoli et al. 2008). Selective COX-2 inhibitors 
decreased both tonic contraction and spontaneous phasic contractions and non-selective 
COX inhibitors did not induce major effects on motility, except for an inhibition of tonic 
contraction shown by flunixin meglumine. This report indicates that the effects of COX 
inhibitors on horse small intestinal motility are not linked to PG depletion. The,precise 
role of COX-l and COX-2 in equine mucosal damage requires further elucidation and 
may provide valu able information for the development of novel therapeutic approaches 
to prevent mucosal in jury and improve survival of hors es with intestinal disease. 
Only one report to date has described COX activity m equme nonglandular and 
glandular gastric mucosa (Morrissey, Bellenger et al. 2008). Authors observed that, in 
both mucosa types, COX-I was the most important pathway to PGE2 production under 
basal circumstances, and COX-2 was the primary pathway when it came to bradykinin-
stimulated tissue in vitro. Neither the expression nor the role of the COX isoforms has 
been reported in equine ulcerated stomach. 
3.6 Clinical Use of Coxibs in Veterinary Medicine) 
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A variety of non-steroidal anti-inflarnrnatory drugs (NSAIDs) target both COX-l and -2 
(DeWitt 1999). These classic COX inhibitors are not selective and the main adverse 
effects of their use in humans are peptic ulceration and dyspepsia. It is believed that this 
may be due to the "dual-insult" of NSAIDs by direct irritation of the gastric mucosa 
since man y NSAIDs are acids, as well as by inhibition of PG synthesis by COX -1. ' 
Recently, selective COX-2 inhibitors (COXIBs) were developed to provide therapeutic 
benefits similar to NSAIDs without the attendant COX-l mediated gastrointestinal 
toxicity (Radi and Khan 2006). Compared with traditional NSAIDs, COX-2 selective 
inhibitors demonstrate a reduced risk of gastric ulceration and decreased gastrointestinal 
side effects; however, this protection is lost if aspirin is coadministrated (Silverstein, 
Faich et al. 2000). However, tradition al NSAIDs and selective COX-2 inhibitors 
reduced epithelial cell proliferation and delayed ulcer healing in rodents (Mizuno, 
Sakamoto et al. 1997; Schmassmann, Peskar et al. 1998), indicating that side effects 
could be anticipated from their use. Moreover, an increase in cardiovascular events has 
been reported in human patients treated with selective COX-2 inhibitors (Bresalier, 
Sandler et al. 2005). 
Although several coxibs have been developed (rofecoxib, celecoxib, valdecoxib, 
parecoxib, etoricoxib, lumiracoxib), most of them have been withdrawn or were never 
approved in humans due to safety concerns. Increased risk of myocardial infarction, 
nephrotoxicity, hepatotoxicity and increased rate of serious and potentially life 
thre.atening skin reactions were the primary side-effects related to coxib use in humans 
(Schneeweiss, Solomon et al. 2006; Solomon, A vom et al. 2006; Yan, Leung et al. 2006; 
Laine, White et al. 2008). Gastro-intestinal side effects were also cornrnon in patients 
who received coxibs (Laine, Connors et al. 2003; Schnitzer, Burmester et al. 2004). Co-
administration with proton-pump inhibitors, such as omeprazole, was frequently 
recornrnended in cases of long term treatment (Bertin and Avouac 2003; Targownik, 
Metge et al. 2008). 
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In veterinary medicine, to date, only deracoxib and firocoxib have been approved for 
administration in dogs (Clark 2006), and ônly firocoxib has been approved for use in 
horses (Doucet, Bertone et al. 2008). 
Deracoxib selectiveness for COX-2 was demonstrated in dogs through an in vivo study 
(Sessions, Reynolds et al. 2005), and its effectiveness in preventing pain' and lameness 
associated with synovitis waS shown in an experimentally-induced model (Millis, 
Wei gel et al. 2002). In dogs with osteoarthritis, treatment with deracoxib did not alter 
platelet function; however hypercoagulability with increased clot strength and high 
coagulation index was reported (Brainard, Meredith et al. 2007). Three day treatment 
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with deracoxib in clinically normal dogs did not alter the macroscopic appearance of 
pyloric or duodenal mucosae nor lead to histological evidence of ulceration in those 
tissues (Wooten, Blikslager et al. 2008). In the same study, deracoxib had no effect on 
mucosal COX-2 protein expression; however mild to moderate abnormalities were 
evident in pyloric antral and duodenal biopsy specimens. Deracoxib decreased gastric 
PGE2, but not PGE\ concentration after 3 days of treatment (Sessions, Reynolds et al. 
2005). Deracoxib administered orally once a day at 4 mglkg worsened the endoscopic 
score of gastric fundus, antrum and lesser curvature of five healthy dogs one day after 
administration (Dowers, Uhrig et al. 2006). Less than a year after deracoxib approval in 
the United States, the Novartis pharmacovigilance database had registered 29 cases of 
dogs with gastrointestinal tract perforation, however in 90% of the cases, deracoxib had 
been administered at higher-than-approved dosage or in close temporal association with 
another NSAID or corticosteroid (Lascelles, Blikslager et al. 2005). 
In a clinical trial that enrolled more than 1000 client-owned dogs, another coxib tested in 
dogs, firocoxib, was considered effective at minimizing osteoarthritis pain and 
improved the quality of life of more than 87 % of the patients at Days 10 and 40 (Ryan, 
Moldave et al. 2006). In the same study minimal side effects were reported. When 
firocoxib was used at the recommended dosage for 28 days on healthy dogs, no side 
effects were registered (Steagall, Mantovani et al. 2007). In another trial, firocoxib-
treated dogs had greater improvement in the clinical signs of osteoarthritis and fewer 
·1 
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abnormal treatment-related events than etodolac-treated dogs (Hanson, Brooks et al. 
2006). On a mixed four-period crossover study design in dogs (Drag, Kunkle et al. 
2007), firocoxib's capacity to pre vent pain in a urate-induced lameness model was 
equivalent to the other NSAIDs being tested (i.e. carprofen, deracoxib and meloxicam). 
In a similar trial, firocoxib was considered better than carprofen to reduce acute pain and 
improve weight bearing (Hazewinkel, van den Brom et al. 2008). Firocoxib suppressed 
plasma and synovial fluid concentrations of PGE2 in osteoarthritic dogs (Punke, Speas et 
al. 2008), and caused 4 of the 8 dogs enrolled in the study to vomit. One study reported 
that 20% of 110 dogs being treated with firocoxib for 30 days had at least one physical 
condition recorded by the owner (Pollmeier, Toulemonde et al. 2006), including 
anorexia, constipation, diarrhea, emesis and polydipsia. Firocoxib slowed wound healing 
in a canine gastric mucosal in jury model (Goodman, Torres et al. 2009). 
Finally, a novel coxib is now being tested for use in companion animaIs. Robenacoxib 
selectivity for COX-2 exceeded 450 for both IC50 and IC80 COX-l/COX-2 ratios in 
feline whole blood assays (Giraudel, Toutain et al. 2009). fi a preclinical study in rats, 
robenacoxib produced less gastric ulceration and intestinal permeability than diclofenac 
and had no relevant effects on kidney function (King, Dawson et al. 2009). It was shown 
that robenacoxib has a good bioavailability in dogs after oral and subcutaneous 
administration (Jung, Lees et al. 2009). 
To date, few studies have been performed concerning the use of coxibs in horses. The 
highly selective COX-2 inhibitor in dogs, deracoxib, was shown to reduce the recovery 
of intestinal mucosal transepithelial electrical resistarice after ischaemia in horses 
(Tomlinson and Blikslager 2005): The same study showed that deracoxib reduced the 
levels of PGE2 and 6-ketoPGF la on ischaemic-injured equine jejunum. 
In a controlled clinical trial, 123 horses with osteoarthritis received 0.1 mg/kg of 
firocoxib once a day (Doucet, Bertone et al. 2008), from those, 104 patients (84.6%) 
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were considered to show improvement of their clinical condition while no direct 
tieatment-related adverse effects were perceived during the study. 
Evidence suggests that most common side effects of coxibs in veterinary medicine are 
related to the GIT~ The effects of COX-2 inhibition on the healing of EGUS lesions 
should therefore be investigated. Characterizing COX-2 expression in normal and 
u1cerated gastric mucosa is a first step towards that objective. 
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OBJECTIVE 
The objective of the present study was to characterize the expression of COX-I and COX-2 
isoenzymes in normal equine nonglandular stomach and in spontaneous eqiIine nonglandular 
gastric u1cers. 
The departure hypothesis was that COX-I would remain with the same expression levels in both 
mucosa types. And COX-2 would be up-regulated in the ulcerated mucosa. 
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Summary 
Objective 
Characterize the expression of the cyclooxygenase-l (COX -1) and cyclooxygenase-2 
(COX-2) isoforms in naturaHy occurring equine nonglandular gastric u1cers. 
Sample Population 
Thirty-eight u1cerated and ten healthy equine stomachs. 
Procedures 
Two specimens of each sample were taken from the gastric squamous mucosa, one was 
fixed in 10% formalin for immunohistochemistry and another was frozen at -70 oC for 
immunoblotting analysis. Immunnoreactivity to two antibodies, MF241 (selective for 
COX-1) and MF243 (selective for COX~2) , was evaluated by a veterinary pathologist 
using a scoring system from 0 to 3, where 0 denoted the absence of COX expression and 
3 corresponded to the maximum expression of either COX isoform. COX-1 and COX-2 
characterizations were confirmed by immunoblotting analyses. 
Results 
AH normal samples strongly expressed COX-l, while only 20% expressed COX-2. The 
expression of both isoforms varied greatly in the ulcerated mucosal samples. The 
expression of COX-1 was significantly lower while the expression of COX-2 was 
significantly higher in ulcerated versus normal mucosae (p <0.0001). 
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Conclusions and Clinical Relevance 
An increased expression of COX-2 in equine squamous gastric u1cers suggests a role for 
this enzyme in gastric u1cer healing. Further studies are necessary to establish the impact 
of COX-2 inhibitors utilization in horses with EOUS. 
30 
Abbreviations 
cox . Cyclooxygenase 
COX-l Cyclooxygenase-l 
COX-2 Cyclooxygenase-2 
DAB Diaminobenzidine tetrahydrochloride 
EGUS Equine gastric ulcer syndrome 
NSAID Non-steroidal anti-inflarnmatory drug 
PBS Phosphate Buffered Saline 
PMNs Polymorphonuclear leukocytes 
RT Room temperature 
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Introduction 
The nonglandular (or squamous) form of the equine gastric ulcer syndrome (EGUS) is a 
widespread disease complex that often affects horses a. The high prevalence illustrated 
by different authors ranges between 40%, in western performance horses l, to 93,6%, in 
Standardbreds in active race training2-4 • In adult horses, ulcers are typically formed in 
the squamous mucosa alongside the margo plicatus, nevertheless they can also be found 
in the glandular and pyloric areas 2,5,6. While many theories related to the mechanical 
consequences of exercise and other potential risk factors have been proposed to explain 
the location and pathogenesis of gastric ulcers in the nonglandular portion of the equine 
stomach7,8 5,9-12; the molecular pathogeneses of ulcer formation and healing have yet to 
be elucidated. 
In essence, the role of the two cyclooxygenase isoforms, COX-l and COX-2, on gastric 
mucosaI defence has been studied in several species, yet information is lacking 
concerning eqJ.line patients. In horses, ulceration of the gIanduIar portion of the stomach 
resembles the situation in other species. However, the pathophysiology of nonglandular 
equine gastric ulcers is thought to be diverse due to different physiologic and defence 
mech~nisms proper to this mucosa. In the glandular gastric mucosa, a complex 
protection system exists to strengthen its resistance against injury. Prostaglandins play a 
crucial role in this system. In the gastrointestinal tract (GIT), maintenance of mucosal 
integrity was initially attributed exc1usively to the COX-I isoform with no contribution 
of COX-2 13 Induction of COX-2 was associated with pathophysiological reactions 
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su ch as inflammation. Recently, studies have shown that COX-2 may also have 
regulatory functions under physiological conditions 14,15. These observations indicate 
that both COX -1 }nd COX -2 either alone or in concert contribute to maintaining gastric 
mucosal integrity in species where glandular ulcers, predominate. Only one report to 
date has described COX activity in equine nonglandular and glandular gastric mucosa 16. 
Authors observed that, in both mucosa types, COX-l was the most important pathway to 
PGE2 production under basal circumstances, and COX-) was the primary pathway when 
it came to bradykinin stimulated tissue in vitro. 
Cyclooxygenase-l and -2 have also been shown to play a role in ulcer healing in several 
species in which the stomach is composed primarily of glandular mucosa. For example, . 
in rats with chronic ulcers, the immunoreactivity of COX-2 was low in normal gastric 
wall and increased in tissue located at the ulcer base 17. Further evidence that COX-2 
plays an important role in acceleration of ulcer healing has also been demonstrated in 
studies where the administration of selective COX-2 inhibitors prevented ulcer healing17 . 
In fact, NSAIDs which inhibit both COX-l and COX-2 have been shown to impair the 
ulcer healing process in species with predominantly glandular mucosae. Since the 
development of new COX-2 selective agents for use in horses, it became imperative to 
comprehend the role of this enzyme on the molecular pathogenesis of EGUS. The 
objective of this study was therefore to characterize the expression of both 
cyclooxygenase isoforms in naturally occurring equine gastric ulcers of the nonglandular 
(squamous mucosa),' in order to establish whether or not the use of new selective 
NSAIDs would be dangerous to horses. 
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Materials and Methods 
Tissue Sample Collection and Anti-COX Antibodies 
U1cerated and normal stomachs from horses slaughtered at an abattoir in St-Aimé, 
Québec, by use of the free bullet method, were used in this study. Care was taken to 
include u1cerated and peripheral mucosa for each sample representing the u1cerated 
stomachs. AlI samples were rinsed in saline solution to remove gastric contents before 
being fixed in 10% neutral buffered formalin or being transported on ice until they could 
be placed in a freezer at -70 oC for immunoblotting analysis. Normal and u1cerated 
samples were evaluated by exarnination of haematoxylin-eosin-saffron-stained sections 
bya veterinary pathologist l8 . Stomachs with mucosal erosions or normal stomachs with 
evidence of inflammation were excluded. Ten (10) normal and 38 u1cerated samples 
were included in this study. Two anti-COX antibodies (MF241 and MF243)b were used. 
MF241 was raised in rab bits against ovine placental COX -1 and its selectivity for COX-
1 has been shown 19. MF243 was raised in rabbits against ovine placental COX-2 and its 
selectivity for equine COX-2 has previously been characterized2o. 
Immunohistochemistry 
Immunohistochemical staining was performed based on a previously described method 
21,22. Briefly, formalin-fixed tissues were paraffin-embedded and 3-!..lm-thick sections 
------------- -----------
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were prepared, deparaffinised in toluene, and hydrated through a graded alcohol series. 
Endogenous peroxidase was quenched by incubating t~e slides in 0.3% hydrogen 
peroxide in methanol for 30 min. After rinsing in PBS for 15 min, sections were 
incubated with normal goat serumc (1:74 dilution) for 20 min at room temperature (RT). 
Primary antibodüis diluted in phosphate buffered saline (PBS) were applied (MF241 at 
1 :4000 dilution and MF243 at 1: 10000 dilution) and sections were incubated overnight 
at 4C. Control sections were incubated with nonimmune rabbit serum. After rinsing in 
PBS for 10 min, a biotinylated goat anti-rabbit antibodyc (1 :222 dilution) was applied, 
and sections were incubated for 45 min at RT. Sections were washed in PBS for 10 min 
and incubated with the avidin DH-biotinylated horseradish peroxidase H reagentsb for 
45 min at RT. After a PBS wash for 10 min, the reaction was revealed using 0.5 mg/ml 
diaminobenzidine tetrahydrochloride (DAB)d in Tris buffer (pH 7.6) as the chromogen 
and 0.05% hydrogen peroxide as the substrate. Sections were counterstained with Gill's 
haematoxylin and mounted. Irnmunoreactivity was evaluated by an independent 
observer using the scoring system proposed by Lajoie and cOlleagues22 , where a score of 
o denoted no staining; 1, 0-10% of positive cells; 2, 11-30% of positive cells and 3, 
2:31 % of positive cells. 
Solubilized Cell Extracts and Irnmunoblotting Analysis 
The immunoblotting technique used in this study has been previously described for 
porcine stomachs22. Briefly, solubilised cell extracts were preparedas previously 
described 23. The protein concentration in each extract was determined by the method of 
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Bradford (Bio-Rad Protein Assay). Proteins were resolved by onedimensional SDS-
PAGE and electrophoretically transferred to Hybond polyvinylidene difluoride 
membranes. Blocking of membranes. was done using 5% non-fat dry milk in 0.1 % 
TTBS (0.1% Tween-20, 10 mM Tris-buffered saline, pH 7.5) for 1 hr at RT, then 
washed twice for 2 minutes at RT with 0.1 % TTBS. After blocking, membranes were 
incubated with anti-COX antibodies (MF241 at 1:4000 dilution and MF243 at 1:7500 
dilution) diluted in 0.05% TTBS (0.05% Tween-20, 10 mM Tris-buffered saline, pH 
7.5) containing 2% non-fat dry milk for 2 hr at RT. Membranes were incubated with a 
horseradish peroxidase-labelled donkey anti-rabbit secondary antibodye (1:15,000 
dilution) for 1 hr at RT. The membranes were washed and the bound secondary antibody 
was detected using the enhanced chemiluminescence's (ECL) detection ki{ The signal 
was visualized on Kodak Bio-Max X-ray filmf. 
Statistical analysis 
Statistical analyses were performed using computer software (SAS V.9.1)g. The 
Cochran-Mantel-Haenszel test assuming unequal distances between scores was used to 
establish the association of the gastric mucosa status and the COX immunoreactivity 
expression and the correlation between the expression of COX-l and COX-2. A value of 
P'S. 0.05 was considered significant. 
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Results 
~ormal samples 
AlI (100%) normal stomachs strongly expressed COX-l but only 20% expressed COX-2 
(Table 1). COX-l staining in normal stomachs was generalIy seen in celIs located in the 
chorion under the epithelial surface and identified as fibroblasts, in blood vessels located 
in the mucosa, submucosa and muscularis layers, and sometimes in smooth muscle celIs 
(Figure 1). The surface epithelium was consistently negative for COX-l. When present, 
COX-2 staining was observed in smalI cells in the muscularis mucosa which were 
thought to probablybe capillaries. COX-2 staining was negative in the surface 
epithelium, in the mucosa and submucosa (Figure 1). 
Ulcerated samples 
Both COX-l and ÇOX-2 were expressed in ulcerated samples although the intensity of 
staining varied considerably (Table 1). When present, COX-l inimunoreactivity in 
ulcerated samples was principally located in fibroblast-like cells under the ulcerated 
surface (Figure 2). When compared with COX-l èxpression in normal samples, a 
significant lower COX-l expression was observed in ulcerated tissues (p<O.OOO1). 
COX-2 immunostaining was predominantly located in the cytoplasm of elongated 
fibroblast-like cells in the granulation tissue proliferating under the ulcerated area. 
COX-2 immunoreactivity was also present in the cytoplasm of mucosal epithelial cells 
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bordering the ulcers (Figure 3). COX-2 expression was significantly higher in ulcerated 
tissues compared to the normal stomach (p<O.OOOl). There was no significant 
correlation between the expressions ofCOX-l and COX-2 (p=0.41). 
Immunoblotting 
When a selective anti-COX-lantibody was used, a 69,000 Mf band was detected in both 
normal and ulcerated stomachs. In several extracts of gastric ulcers, COX-l protein 
levels were markedly reduced (Figure 4A), confirrning the immunohistological 
observation of lower COX-l expression in ulcerated tissues. When a selective anti-
COX-2 antibody was used, no signal wasdetected in normal stomachs but a strong band 
was observed in the protein extracts from gastric ulcers (Figure 4). Equine COX-2 
appeared as a 72,000- 74,000 Mf doublet and a small 62,000 Mf band believed to 
d l . f . l bd' h . 22 24 25 correspon to a proteo Y tIC ragment, as prevIOus y 0 serve 10 ot er specles ' , . 
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Discussion 
This is the first study looking at the expression of COX-l and COX-2 in u1cers of the 
nonglandular portion of the equine stomach .. Our results demonstrate that normal 
nonglandular equine gastric mucosa expresses COX -l, and that most stomachs do not 
express COX-2. This observation is in agreement with previous studies performed on 
human squamous oesophagus mucosa and on nonglandular gastric mucosa in pigs 
22,26,27. They are also in line with common knowledge that COX-l is the constitutive and 
COX-2 the inducible isoform of cyclooxygenase in most tissues. Unexpectedly, 
however, COX-l expression was found to be significantly decreased in nonglandular 
ulcerated tissues. In fact, while COX-l is known to be involved in the complex process 
of mucosal protection in glandular mucosa and has been shown to increase in rats after 
experimentally-induced glandular gastric ulceration 17 , the role of this COX isoform in 
nonglandular mucosal homeostasis is unclear. Yet, a sirnilar decrease in COX-l was also 
observed in porcine naturally-occurring nonglandular gastric u1cers22 As in horses, 
porcine ulcers are located in the nonglandular portion of the stomach. A possible 
explanation for the decrease in COX-l expression in both equine and porcine 
nonglandular mucosal u1cers could be the loss of normal submucosa with its COX-l 
positive cells and its replacement by granulation tissue containing COX-2 expressing 
fibroblasts. Alternatively, it could result from a negative feedback following the increase 
in COX-2, although no correlation was found between COX-l and COX-2 expression in 
ulcerated gastric mucosal samples in this study. 
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COX-2 expression was significantly induced in the ulcerated squamous mucosa of adult 
horses. The same response was reported in pigs 22. Indeed, in naturally occurring 
porcine ulcers of the nonglandular portion of the stomach, COX-2 was also strongly 
expressed (80%) compared to normal mucosa where COX-2 expression was absent or 
very low 22. In the present study, COX-2 expressing cells were predominantly 
fibroblasts present in the granulation tissue under the ulcer bed. The localization of 
COX-2 expression in the granulation tissue in equine ulcers suggests that the enzyme 
cou Id be involved in the repair process of equine gastric ulcers. 
The role of COX-l and COX-2 in glandular ulcer healing has been elucidated largely 
due to the development of COX-l and COX-2 knockout mice and selective COX-l and 
COX-2 inhibitors. Wild-type, COX-l-/- and COX-2-/- mice with gastric ulcers were 
treated with selective COX-l (SC-560), COX-2 (celecoxib, rofecoxib, and valdedoxib) 
and nonselective COX (piroxicam) inhibitors 28. Healing was moderately impaired by 
COX-2 genè disruption and COX-2 inhibitors. Severe healing impairment was observed 
in dual (SC-560 + rofecoxib) and unselective (piroxicam) COX inhibition and combined 
COX impairment (in COX-l-/- mice with COX-2 inhibition and COX-2-/- mice with 
COX-l inhibition). Inhibition of COX-l or gene expression had no effect on ulcer 
healing. It is not known if the same response is seen on nonglandular ulcer healing 
although delayed ulcer healing caused by selective COX-2 inhibition has been shown to 
be due to a reduction in epithelial cell proliferation in rat esophageal ulcers29 . 
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Cyc100xygenase-2 stimulus has been shown to be the mam pathway leading to 
endogenous prostaglandins' contribution to ulcer healing in the glandular gastric mucosa 
17,30,31. Prostaglandins are believed to contribute to glandular ulcer healing through the 
induction of hepatocyte growth factor32 , reduction of gastric acid secretion33-35 , 
angiogenesis36 and stimulation of mucus and bicarbonate secretion37,38. 
Cyc100xygenases have also been shown to be involved in ulcer healing as COX-2 
mRNA and protein were increased in gastric ulcers induced by subserosal injection of 
acetic acid in mice 31 while no effect on COX-I mRNA expression was observed in 
ulcerated or non-ulcerated mucosae. A threefold increase in prostaglandin (PGA2, PGE2, 
PGF2u) levels was demonstrated in ulcerated tissue when compared to normal tissue and 
was inhibited by exposure to the COX-2 inhibitor NS-398 31 indicating that those ' 
prostaglandins were synthesised principally via the COX-2 pathway. These data 
suggested that, at least in glandular-type mucosae, COX-2 is an important mediator in 
promoting ulcer healing and COX-l becomes important when COX-2 is impaired. It is 
not c1ear whether the same mechanisms can be inferred to nonglandular type mucosa 
su ch as in horses 
COX-2 immunoreactivity was primarily located in fibroblasts at the ulcer base in this 
study. Similarly, in rats with chronic ulcers, the immunoreactivity of COX-2 was low in 
normal gastric wa]] and strongly increased in the tissue of the ulcer base 17 where it was 
identified in the cytoplasm of different cell types situated in regions of maximal repair 
activity. Immunoreactivity of COX-l was located mainly in the non-ulcerated mucosa 
and was reduced after gastric ulceration in the mucosa adjacent to the ulcer crater. In the 
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same rat study, COX-1 immunoreactivity reappeared from day 5 onwards in the apical 
cytoplasm of the regenerative epithelial cells. Although the evolution of COX 
expression could not be assessed in this present in vitro study, the observations from 
rodent studies suggest that in chronic u1c~rs COX-1 and COX-2 may have different 
locations and different times of expression. If COX-2 is up-regulated in chronic gastric 
u1cers and inhibitors of COX-2 prevent the healing of u1cers then COX-2 may play an 
important role in acceleration of u1cer healing. Prostaglandins inhibit leukocyte 
adherence to the vascular endothelium39, improving the resistance of the gastric mucosa 
to injury through the down regulation of inflammatory responses40,41. PGD2 derived 
from the COX-2 pathway decreased granulocyte infiltration in experimentally induced 
colitis in rats42 . COX-2 derived PGD2 metabolite was shown to mediate PMNs and 
macrophages apoptosis during resolution of acute inflammation43 . Recent findings in 
rats further support this hypothesis as selective COX-1 inhibition was shown to result in 
a reduction in gastric mucosal blood flow while selective COX-2 inhibition increased 
leukocyte adherence in mesenteric venules suggesting that the two COX isoforms differ 
in their biological activity 44. It is unknown if these mechanisms apply as well to 
nonglandular u1cers. 
In conclusion, this in vitro study suggests that, as demonstrated for glandular gastric 
tissue of rodents 28,45,46, COX-2 may play an important role in equine gastric u1cer 
healing in the nonglandular mucosa. Further studies are required to elucidate the clinical 
relevance of these findings and the potential impact of the administration of selective 
COX-2 inhibitors (such as firocoxib) on gastric u1cer healing in horses. 
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Footnotes 
a Picavet M-T. The Equine Gastric Ulcer Syndrome (EGUS) and preventive 
feeding. Proceedings of First European Equine Health and Nutrition Congress 
2002. 
b Merck Frosst Centre for Therapeutic Research, Point-Claire, Dorval, Québec, Canada. 
'c Vectastain ABC kit, Vector Laboratories, Burlingame, CA. 
d Sigma-Aldrich, Oakville, Ontario, Canada. 
e Amersham Life Sciences, Arlington Heights, IL. 
f Eastman Kodak, Rochester, NY. 
g SAS Institute, Cary, Ne. 
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Table 1: Cyclooxygenase-l (COX-l) and Cyclooxygenase-2 (COX-2) Scoring 
Frequency According to Mucosal Status 
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Table 1 
COX-l COX-2 
Staioiog Score 0 1 2 3 0 1 2 3 
Normal (0=10) 0 0 0 100 80 20 0 0 
Ulcerated (0=38) 2.6 57.9 29 10.5 7.9 47.4 31.6 13.2 
Frequencies are shown in percentages. 
Figure 1: Cyclooxygenase Expression in Normal Equine Squamous Gastric Mucosa 
A) Section stained with antibody MF241 (selective against COX-l) shows 
immunoreactivity mostly in fibroblast-like cells in the submucosa. 
52 
B) Section stained with antibody MF243 (selective against COX-2) shows no positivity. 
DAB substrate and hematoxylin counterstain. Bar = 50 Ilm. 
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Figure 1 
54 
Figure 2: Cyclooxygenase-l Expression in Ulcerated Equine Squamous Gastric Mucosa 
A) COX-l-positive cells are reduced in number in many ulcers. 
B) Numerous COX~l positive cells are still present in sorne ulcerated stomach. DAB 
substrate and hematoxylin counterstain. Bar = 50 !lm. 
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Figure 2 
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Figure 3: Cyclooxygenase-2 Expression in Ulcerated Equine Squamous Gastric Mucosa 
A-B) Two ulcerated mucosa are shown with several COX-2 positive fibroblast-like 
cells; 
C) COX-2 expression is also present in epithelial cells bordering the ulcer. D) Negative 
control staining with normal rabbit serum (without primary antibody). DAB 
substrate and HE counterstain. Bar = 70 !-lm. 
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Figure 3 
Figure 4: Western Blot Analysis of COX-l and COX-2 Isoforms in Normal and 
Ulcerated Equine Squamous Gastric Tissues 
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A) Blots probed with antibody MF241 (selective for COX-l).COX-l protein is strongly 
expressed in normal stomachs but markedly diminished in 3 out of 5 ulcerated 
samples. 
B) Blots probed with antibody MF243 (selective for COX-2). No COX-2 protein is 
detected in normal stomachs but a strong COX-2 induction is present in all ulcers. 
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DISCUSSION 
The equine stomach is composed of two distinct types of mucosa which have very 
different causes for ulceration. While the glandular portion tends to ulcerate due to non-
steroidal anti-inflammatory drug use in horses of all ages or to stress in foals, risk factors 
for ulceration of the nonglandular portion are mostly related to feeding habits and 
exercise intensity in adult horses (The Equine Gastric Ulcer Council 1999; MeITitt 
2003). The CUITent study performed in adult horses, focused on ulceration of the 
nonglandular portion of the stomach. While the stomachs of most monogastric animal 
species including humans have only glandular type mucosae, the only domestic animal 
species that shares a similar gastric histology with the horse is the pig. As a direct 
comparison, findings from this study will therefore be compared to limited data 
available for the porcine stomach while sorne similarities with human oesophageal 
ulceration (esophageal reflux disease) will also be made since human oesophagus is 
covered in squamous or nonglandular type mucosa as weIl. In light of limited data 
conceming the role of COX isoforms in nonglandular mucosa, studies performed in rats, 
mice and humans which all have exclusively glandular type gastric mucosae will also be 
discussed in an attempt to elucidate the mechanisms by which the expression of COX 
isoforms is modulated in general but indirect fashion. 
This study demonstrates that normal nonglandular equine gastric mucosa expresses 
COX-l, and that most specimens do not express COX-2. Previous studies performed on 
human squamous oesophageal mucosa and on porcine nonglandular gastric mucosa 
(Lajoie, Sirois et al. 2002; Kase, Osaki et al. 2004; Martins, Artigiani Neto et al. 2007) 
reported similar observations and are in agreement with the basic understanding that 
COX-I is the constitutive and COX-2 the inducible isoform of cyclooxygenase in most 
tissues (Herschman 1996; Williams and DuBois 1996). Although general theory would 
predict otherwise, COX-1 expression was significantly decreased in ulcerated equine 
nonglandular mucosa as it has also been reported in porcine naturally-occuITing gastric 
ulcers (Lajoie, Sirois et al. 2002) and in rats after experimentally-induced gastric 
ulceration (Schmassmann, Peskar et al. 1998). While the rat stomach is lined 
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exclusively with glandular mucosa, porcine gastric u1cers are located in the nonglandular 
portion of the stomach, which is similar in structure and function to equine squamous 
mucosa and therefore has a pathophysiology comparable to equine squamous gastric 
u1cers. 
The explanation for this decrease in COX -1 expression remains unclear at the moment. 
It could be hypothesized that this is a consequence of the loss of normal submucosa . 
containing COX-l positive cells and its replacement by granulation tissue containing 
COX-2 expressing fibroblasts. Alternatively, it could result from a negative feedback 
following the increase in COX-2 expression. However, the latter the ory appears less 
plausible since no correlation was found between COX-l and .COX-2 expression III 
u1cerated gastric mucosal samples. 
COX-2 expression was significantly induced in the u1cerated mucosa of adult horses. In 
pigs, COX-2 was also strongly expressed in naturally occurring porcine u1cers of the 
nonglandular portion of the stomach, compared to normal mucosa where COX-2 
expression was absent or very low (Lajoie, Sirois et al. 2002). Cyclooxygenase-2 
(COX-2) expressing cells in thecurrent study were principally fibroblasts and epithelial 
cells located in the granulation tissue under the u1cer bed. Hardly any inflammatory 
cells were COX-2 positive and no correlation was found between either COX isoform 
expression and the intensity of the inflammatory reaction. Nonetheless, the score used to 
assess inflammation was only semi-quantitative. Similarly, in a study in human patients. 
presenting symptoms of gastroesophageal reflux disease (Hamoui, Peters et al. 2004), no 
correlation was found between inflammation and COX-2 levels. COX-2 expression in 
the granulation tissue in equine u1cers suggests that this enzyme could be involved in the 
healing process of equine gastric u1cers. Despite that, it cannot be forgotten that COX-2 
is responsible for PO production during inflammatory processes and is upregulated 
during an inflammatory response (Lee, Soyoola et al. 1992; Xie, Robertson et al. 1992; 
Meade, Smith et al. 1993; Mitchell, Akarasereenont et al. 1993; O'Sullivan, Huggins et 
al. 1993). ThereforeCOX-2 expression could simply be induced on the u1cerated gastric 
mucosa of horses because of its inflammatory functions. 
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Although very little is known of the role of COX-l and COX-2 in nonglandular mucosal 
healing, the development of COX-l and COX-2 knockout mice and selective COX-l 
and COX-2 inhibitors has helped to elucidate the role of COX-l and COX-2 in u1cer 
healing in glandular-type gastric mucosa. Wild-type, cox-r/-and COX-2-1- mice with 
gastric ulcers were treated with selective, COX-l (SC-560), COX-2 (celecoxib, 
rofecoxib, and valdedoxib) and non-selective COX (piroxicam) inhibitors 
(Schmassmann, Zoidl et al. 2006). Healing was moderatelyimpaired by COX-2 gene 
disruption and COX-2 inhibitors. Severe healing impairment was observed in dual (SC-
560 + rofecoxib) and unselective (piroxicam) COX inhibition and combined COX 
impairment (in cox-rl - mice with COX-2 inhibition and COX-2-1- mice with COX-l 
inhibition). Inhibition of COX-l or gene expression had no effect on u1cer healing. In 
rats with esophageal ulcers, il was shown that delayed u1cer healing caused by selective 
COX-2 inhibition was due to a reduction in epithelial cell proliferation (Baatar, Jones et 
al. 2002). Hepatocyte growth factor induction is alleged to be a very important 
contribution of prostaglandins to ulcer healing (Bamba, Ota et al. 1998). Since COX -2 
mRNA and ,protein were increased in gastric ulcers induced by subserosal injection of 
acetic acid in mice (Mizuno, Sakamoto et al. 1997), cyclooxygenases have also been 
shown to be involved in u1cer healing, whilst no effect on COX-l mRNA expression 
was observed in ulcerated or non-ulcerated mucosae. Prostaglandin increase (PGAz, 
PGE2, PGF2a) was demonstrated in ulcerated tissues when compared to normal ones and 
was inhibited by exposure to the COX-2 inhibitor NS-398 (Mizuno; Sakamoto et al. 
1997) demonstrating that those prostaglandins were synthesized principally via the 
COX-2 pathway. AlI of the above suggests that, at least in glandular-type mucosae, 
COX-2 is an important mediator in promoting u1cer healing and COX-l becomes 
imperative when COX-2 is impaired. Whether the same mechanisms can be extrapolated 
to nonglandular type mucosa such as in horses has yet to be clarified. 
In this study, COX-2 immunoreactivity was primarily located in fibroblasts at the ulcer 
base. In rats with chronic ulcers, the immunoreactivity of COX-2 was low in normal 
gastric wall and strongly increased in the tissue of the ulcer base like in our equine 
specimens (Schmassmann, Peskar et al. 1998), where it was identified in the cytoplasm 
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of different cell types situated in regions of maximal repair activity. COX-I 
immunoreactivity was located mainly in the non-ulcerated mucosa and was reduced after 
gastric ulceration in the mucosa adjacent to the ulcer crater. In the same experiment, 
COX-I immunoreactivity reappeared from day 5 onwards in the apical cytoplasm of the 
regenerative epithelial cells. Even though the evolution of COX expression cou Id not be 
assessed in this present in vitro study, the observations from rodent studies suggest that 
in chronic ulcers COX-l and COX-2 may have different spatial and temporal expression 
patterns. If COX-2 is up-regulated in chronic gastric ulcers and inhibitors of COX-2 put 
off the healing of ulcers then COX-2 may play an important role in acceleration of ulcer 
healing. Other findings in rats sustain this hypothesis as selective COX-l inhibition was 
shown to result in a reduction in gastric mucosal blood flow whereas selective COX-2 
inhibition increased leukocyte adherence in mesenteric venules suggesting that the two 
COX isoforms differ in their biological activity (Wallace, McKnight et al. 2000). 
Overall, this study suggests that, as established for gIandular gastric tissue of rodents 
(Shigeta, Takahashi et al. 1998; Takahashi, Shigeta et al. 1998; Schinassmann, Zoidl et 
al. 2006), COX-2 may play an important role in equine gastric ulcer healing of the 
squamous mucosa. Complementary studies are essential to reveal the clinical 
consequence of these findings and the potential impact of the administration of selective 
COX-2 inhibitors on gastric ulcer healing in horses. 
Tracking immunohistochemical changes in gastric specimens before and after 
ulceration, with and without the administration of selective COX-2 NSAIDs is a 
compelling way to study the role of COX-2 on EGUS healing. Trying to do so, the use 
of an endoscopic technique to take multiple biopsies of equine gastric mucosa in vivo 
was evaluated as a secondary pilot project (Appendix 1). The validation of an 
endoscopic biopsy technique that would be safe, repeatable and non-invasive in horses 
wou Id be a step forth to facilitate the study of EGUS pathophysiology over time, 
because it could allow researchers to take multiple samplings with minimal· 
inconvenience to the study subjects. Although the technique was safe, simple to execute, 
and appropriate for the glandular-type mucosae, it was not possible to obtain samples of 
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sufficient size and depth from the nonglandular gastric mucosae of horses used in this 
pilot study. Another technique should be investigated to perform repeated 
transendoscopic biopsies of the nonglandular mucosa of horses with the purpose to 
disclose the pathophysiology of EGUS in vivo. 
----------------------------------
65 
CONCLUSION 
Gastric ulcers have a high occurrence in athlete horses because of intensive training 
practices. Even though several hypotheses have been discussed, the pathogenesis of 
EGUS remains unclear. COX-2 up-regulation associated with gastric ulceration has 
been demonstrated in humans, pigs and now in horses. 
Under physiologie conditions, COX-l is strongly expressed in the equine gastric 
squamous mucosa, while COX-2 is barely discernible. However, when ulcers occur the 
expression of COX-l diminishes and of COX-2 increases. Describing COX-l and 
COX-2 expressions in the gastric mucosa of horses is the first step towards 
understanding the role of these isoenzymes in EGUS pathogenesis and healing. 
Future research should investigate the role of the cyclooxygenase isoforms on equine 
gastric ulcers through an experimentally-induced model where endoscopie gastric 
biopsies would be obtained from healthy and ulcerated mucosa and analyzed by 
immunohistochemistry on a temporal basis. Until then, care is advised when treating 
horses at risk of having EGUS with selective anti-COX-2. 
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Summary 
Reasons for performing the study: In order to study the evolution of histopathologic 
and immunohistochemical changes in the gastric mucosa of horses with EGUS (Equine 
Gastric U1cer Syndrome), a feasible, useful, valid, and safe in vivo gastric biopsy 
technique was required. 
Objectives: To determine the average gastric mucosal healing time following 
endoscopie gastric biopsy sampling and evaluate the feasibility, safety and usefulness of 
samples obtained by this method for histopathological analysis. 
Methods: Six (6) adult mares from the Faculté de Médecine Vétérinaire res,earch herd 
were used. Trans-endoscopie gastric biopsy was performed on days 0 and 9 using a 
flexible forceps with oval and fenestrated jaws to obtain gastric mucosal samples from 4 
different sites: cardia (C), fundus (F), margo plicat{Js (MP) and glandular mucosa (GL). 
A maximum of 4 samples per site was taken.Samples were routinely processed for 
histopathological exarninat!on and evaluated by a pathologist. On days 1 to 4 and 9 to Il 
the lesions created by the biopsies were evaluated by gastroscopy. Lesions were 
\1 
evaluated over time based on a score from 0 to 4, where a score of 4 was considered the 
most severe. 
Results: Biopsy samples could be obtained from aU targeted sites except the cardia. No 
abnormal clinical signs were observed up to 7 days post-biopsy. The average biopsy 
lesion scores decreased significantly with time for all sites. The average lesion score was 
significantly higher for the MP site compared to the other sites at days 1 and 2. Samples 
taken from the nonglandular portion of the stomach were considered inadequate for 
histopathology, while those taken from the glandular mucosa were adequate. 
Conclusion: The transendoscopic gastric biopsy technique described here is a feasible, 
safe and useful technique for obtaining samples from the equine gastric glandular 
mucosa. Although biopsy samples could be obtained from several areas in the non-
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glandular mucosa, these were very small, took longer to heal and were not considered 
adequate for histopathological evaluation. Renee, another technique will need to be 
validated for the nonglandular gastric mucosa. 
78 
Introduction 
Endoscopie gastro-biopsy has been used as a reliable diagnostic method in human 
medicine since the 1970's (Gear and Dobbins 1969; Hatfieldet al. 1975; Kasugai 1970) 
and in companion animal practice for approximately the last ten years (Mansell and 
Willard 2003; Sonea et al. 1999; Willard et al. 2001). Compared to full-thickness 
surgery techniques, endoscopie biopsy is generally preferred because it is less invasive, 
can be do ne under direct vision and allows multiple samples to be taken safely (van der 
Gaag 1994). 
Flexible biopsy forceps are long and thin instruments which can be passed through the 
fulliength of the endoscope insertion tube. These forceps have a clenching bivalved cup 
at the end which is used to grasp and avulse the tissue from its biopsy site (Golden 1993; 
Waye 1981). Most authors agree that forceps with elongated, fenestrated cups yield 
superior quality biopsy specimens than those with round, closed cups. AIso, it is 
considered that the absence of a needle results in deeper specimens compared to forceps 
with a needle (Mansell and Willard 2003; Woods et al. 1999). To ensure an accurate 
diagnosis by fiberoptic endoscopie biopsy of the gastrointestinal tract, it has been 
recommended to take six to eight samples for each anatomie region since pathological 
lesions are often multifocal and heterogeneous in the se tissues (Mansell and Willard 
2003; Waye 1981). In accordance with the same studies, each sample should contain 
mucosa and submucosa (i.e., muscularis mucosa) in order to allow an accurate 
interpretation of histologie findings by the pathologist. 
Regrettably, only a few researchershave reported use of this technique in equine 
patients. In 2002, Murray and colleagues (Murray et al. 2002) presented an abstract on 
endoscopie duodenal biopsy. In this study, biopsies were performed on the duodenal 
ampulla of 15 foals and 54 mature horses using a 3 meter endoscope with a biopsy 
channel diameter of 2.8 mm. Although details of the comparison between endoscopie 
biopsies and full-thickness tissues were not rèported, this procedure appeared to provide 
good quality mucosal specimens in most subjects and comparison with full-thickness 
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biopsies obtained in 6 horses seemed to indicate good reliability. In another abstract 
(Jean et al. 2004), endoscopie duodenal biopsy was performed in 8 horses with 
mal absorption syndrome and 6 control horses. Unfortunately, the instrument used for the 
procedures was not described. Specimens containing both mucosal and submucosal 
tissues were obtained and were adequate for histopathologic diagnosis of several types 
of enteritis within the malabsorption syndrome group. - This study also showed that 
duodenal endoscopie biopsy was weIl tolerated by the horses. 
The only full paper publication on equine gastric endoscopie biopsy (Murray et al. 2004) 
describect a novel technique for obtaining larger sized biopsies in the gastrie antrum of 
horses for microscopie diagnostic purposes. Fifteen (15) mature horses were used. The 
technique consisted of attaching a potypectomy snare on the outer part of the endoscope 
and connecting it to a unipolar electrocautery unit. A biopsy forceps was used to grab 
the mucosa while the loop was closed around it and the electrocautery was activated. 
Generally, the samples were of reasonable size, included the entire mucosa and were 
considered satisfactory for histologieal examination. The majority of horses had 
negligible bleeding and no discomfort related to this biopsy technique however the 
healing process was not assessed past day 1. 
To date, aIl information published regarding endoscopie gastro-intestinal biopsy in 
horses has been favourable with regards to safety and acceptability of samples obtained 
for histopathologic evaluation. However, none of the studies discussed above have 
assessed the healing process of the lesions created on the gastrie or intestinal mucosa 
which is an important criterion to evaluate when considering multiple sampling over a 
short period of time for research purposes. Furthermore, evaluation of sample quality in 
various regions of the gastric mucosa has not yet been reported in the horse. For the 
study of the pathophysiology of EGUS or other gastric pathologies in vivo, samples from 
different anatomie regions in the equine stomach cou Id be of great value. The purpose 
of this study was therefore to investigate the feasibility, healing time, safety and 
usefulness of a trans-endoscopie gastric mucosal biopsy technique for multiple sampling 
of various sites in the stomach in adult horses. 
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Materials and methods 
Study subjects 
Six (6) Standardbred and Arab breed mares from the research herd of the Faculté de 
. médecine vétérinaire (FMV), aged between 8 and 15 years and weighing between 420 
and 540 kg were used. Mares were housed at the FMV equine research facility, kept in 
their normal environment and fed their standard ration for the duration of the study. 
Horses that presented clinical signs of systemic disease and/or behavioural problems 
were considered unsuitable. In order to. confirm inclusion in the study, a complete 
physical exarnination was performed on Days 0 and 9 including assessment of 
temperature, heart and respiratory rates as weIl as a complete physical examination. 
Study design 
Endoscopie biopsies were performed on days 0 and 9. Daily gastroscopie exarninations 
, 
were carried out on days 0 to 4 and 9 to Il in order to evaluate mucosal healing and 
c1inical safety of the gastric biopsy technique. AU horses were fasted for a minimum of 
12 hours prior to each gastroscopie exarnination. On days 1 to 4 and 9 to Il the lesions 
created by the biopsies were evaluated by endoscopy in order to assess their evolution 
over time. AlI gastroscopies, biopsies and evaluations of the lesions were recorded with 
a digital video camera for further evaluation. The experimental protocol was approved 
by the Institutional Animal Care and Use Committee (CEUA, Faculté de médecine 
vétérinaire, Université de Montréal). 
Trans-endoscopie gastric biopsy technique 
Endoscopy was performed as previously described (Roy et al. 2005). Xylazine 
hydrochloride (AnaSed, 0.5mg/k:g, i.V.)l was administered as needed for minimal 
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sedation. Four distinct sites, namely cardia (C), fundus (F), margo plicatus (MP) and 
glandular mucosa (GL) were targeted for sampling. At most, 4 specimens were taken per 
site. A reusable, 3 m long, oval shaped, fenestrated distal cup forceps (model 
KW2430S)2 (Figure 1) measuring 2,4 mm in diameter' was inserted via the 2.9 mm 
diameter working channel of the endoscope2 • The tip of the endoscope was placed at a 
nearly 90 degree angle with the gastric mucosa, and the forceps was advanced to grasp 
the mucosa with its open jaws. The forceps was then closed quickly and tightly while the 
endoscope was held as straight as possible to protect the biopsy channel and allow the 
retraction of the forceps. Next, the forceps was briskly pulled back through the 
endoscope thus sectioning the tissue in the process. The biopsy samples were carefully 
removed and immediately fixed in 10% neutral buffered formaI in while the endoscope 
remained in position for collection of other samples. 
Evaluation of clinical safety 
Daily records assessmg health status, appetite, feces appearance, concomitant 
medications, health problems, temperature, pulse and respiration were completed from 
Days 0 to 13 in order to assess clinical safety of gastric biopsies. 
Evaluation of biopsy lesions 
The healing process of the gastric mucosa was assessed, using the recorded videotapes 
of gastroscopies performed on Days 1, 2, 3, 4, 9, 10 and 11, by two independent 
evaluators. The worst lesion per site was considered for evaluation, using a newly 
established visual scoring system based on macroscopic ch~nges observed during 
gastroscopy described in Table land illustrated in Figures 2 and 3. 
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Evaluation of biopsy sample usefulness 
AlI formalin-fixed tissues were routinely processed, embedded in paraffin and cut into 
sections of 3-!.tm thickness. Tissues sections were stained with hematoxylin, eosin, 
phloxin and safran, and evaluated· by a pathologist. Specimens were classified as' 
adequate or inadequate for histopathologic diagnosis based on quality, size and depth. 
Data analysis 
Statistical analyses were performed using computer software (SAS V.9.1l The kappa 
coefficient was used to determine the agreement between the evaluators for the' 
assessment of lesion healing scores. The Cochran-Mantel-Haenszel (CMH) test for 
repeated measurements, using site as a categorical variable and day and score as ordinal 
variables was used to establish the effect of time and site on the lesion score. The effect 
of day (1 versus 9) of biopsy was also evaluated using the CMH test. Values were 
considered significant at p <0.05. 
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Results 
Five horses completed the study. One horse was removed at day 7 due to behavioural 
problems that were unrelated to the study. No other adverse events were observed during 
the period of this study. 
Biopsy samples could be obtained from aIl targeted sites except the cardia region 
because of technical impediment. On day 0, 24 and 23 samples were collected 
respectively from the fundus and the margo plicatus of 6 mares. Because of significant 
post-biopsy bleeding of the glandular gastric mucosa in the first two horses, a total of 4 
samples (2 per mare) were collected from this site on Day 0 until further assessment 
could be made of short-term healing and side-effects. Furthermore, due to their very 
small size, sorne nonglandular mucosal samples were lost in the process of preparing the 
histology slides leading to decreased sample numbers from Day 1. On day 9, in order to 
increase or complete the number of samples at each site, ten (10) samples were collected 
from the fundus of 4 mares while 8 samples from the margo plicatus and 17 samples 
from the glandular gastric mucosa were collected from 5 subjects. AlI new samples 
obtained on day 9 were obtained in regions where biopsies had not been performed on 
Day 0 in any given subject. Daily median lesion scores for each site are presented in 
Figure 4. As statistical analyses confirmed that there was no effect of day of sampling on 
lesion score change over time, scores from biopsies performed on day 0 were combined 
with those taken on Day 9. A kappa coefficient of 0.66 indicated a good agreement 
between evaluators for lesion scores while; only data from the senior evaluator were 
used for the Cochran-Mantel-Haenszel test. 
Lesion scores presented a significant temporal linear decrease for all sites (p=0.02, 
p<O.OOOl and p=0.0002 for sites GL, MP and F, respectively). 
Significant differences were found between average lesion scores by site on Days 1 and 
2 (p = 0.005 and p = 0.007, respectively). Further two by two comparisons indicated 
" 
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that the average lesion score was significantly higher in site MP than in site GL or site F 
while there was no significant difference between site GL and site F. 
Histopathologic evaluation revealed that aIl biopsy specimens obtained from the 
. nonglandular squamous mucosa were inadequate and samples from' the glandular 
mucosa were adequate for diagnostic purposes. In general, samples obtained from aIl 
sites weœ very smaIl, in the range of 2x2 mm for the nonglandular samples and 3x3 to 
4x3 mm for the glandular samples (Figures 5A and 5C). Samples collected from the 
glandular portion of the stomach contained the entire mucosa and the superficial portion 
of the lamina propria, while the nonglandular samples contained only the stratified 
squamous epithelium (Figure 5). 
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Discussion 
In accordance with previous studies on equine gastro-intestinal endoscopie biopsies, no 
adverse clinical signs were observed, indicating that the technique described in this 
study is clinically safe when repeated twice within 9 days (Jean et al. 2004; Murray et 
al. 2004; Murray et al. 2002). 
The transendoscopic biopsy technique was generally simple to execute for all regions, 
except the cardia. At this site, it became impossible to direct the forceps close enough- to 
the mucosa because of the flexed position the endoscope takes when observing the 
cardia. 
\ 
Furthermore, it is of note that, as others have reported in dogs (Tams 1990), when the 
gastric folds are flattened it becomes more diffieult for the forceps to hold and grasp the 
mucosa in horses. Therefore, it is recommended to avoid over distending the stomach 
with air, as is frequently do ne with most gastroscopic examinations in horses. 
Although it has not been validated using post-mortem tissue samples as a gold standard, 
the lesion scoring system used on this study was found to be useful as a visual reference 
and estimate of lesion evolution over time. Healing time was significantly delayed in the 
nonglandular margo plicatus compared to the nonglandular fundus or the glandular 
mucosal sites in this study. The glandular mucosa, for one, is histologicaIly different and 
physiologically better adapted to healing in an acidic environment compared to the 
nonglandular mucosa in general. In fact, defence mechanisms such as surface mucus 
secretion, bicarbonate secretion into mucus, mucosal blood flow, apical surface 
membrane transport, epithelial regenerative capacity and elaboration of prostaglandins 
(Crawford and Kumar 2003; Gelberg 2007; Herdt 2007; Sjaastad et al. 2003) most likely 
contributed to the relatively rapid healing of biopsy lesions performed at this site. 
Although, the nonglandular mucosa also benefits from defence mechanisms to aid in 
repair, primarily associated with its histological characteristics (Murray 1994; Picavet 
2002; The Equine Gastric Ulcer Council 1999), it is not weIl adapted to continuaI 
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exposure to destructive elements such as acid and pepsin. Hence, biopsy lesions created 
along the nonglandular margo plicatus may have healed slower because of the constant 
proxirnity of the gastric juices. This has also been proposed to explain why naturally 
occurring gastric ulcers of the nonglandular mucosa are more predominantly found 
along the margo plicatus in adult hors es (Bezdekova et al. 2007; Dionne et al. 2003; The 
Equine Gastric U1cer Council 1999). 
The fact that samples obtained in.this study were generally of very small size could be 
deemed as one disadvantage of using the transendoscopic gastric biopsy technique since 
the size of the biopsy sample is lirnited by the size of the biopsy channel of the 
endoscope (Tams 1990). This also likely contributed to the po or quality of the histologie 
samples obtained from the nonglandular mucosa compared to the larger ones obtained 
from the glandular mucosa. 
In conclusion, the transendoscopic technique described in this study yielded samples of 
adequate size and depth for histopathologic asses~ment of gastric biopsy samples taken 
in the glandular mucosa of horses. However, in order to perform repeated 
transendoscopic biopsies of the nonglandular mucosa for diagnostic or investigative 
purpose, other techniques using different instruments should be investigated with the 
intention of obtaining larger and deeper samples. Serrated edge biopsy cups have been 
reported to pro vide larger samples than straight edge forceps (Tams 1990). The addition 
of serrated forceps to the multiple bite approach could possibly grant enough material 
for satisfactory histological diagnosis of the nonglandular squamous mucosa in horses as 
weIl. The use of the polypectomy snare, as proposed by Murray and colleagues for 
obtaining samples from the gastric antrum could be another interesting option for 
obtaining biopsies in this region of thè equine stomach (Murray et al. 2004) .. 
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Table 1: Gastric Biopsy Lesion Scoring System 
Score 
o 
1 
2 
3 
4 
Table 1 
Description 
Intact rnucosa (lesion no longer detectable) 
Intact rnucosa with sorne redness 
91 
Granulation tissue covers entire lesion although healing rernains incornplete 
Sorne granulation tissue and contraction of lesion (initial healing) 
Fresh lesion with or without bleeding (no appearance of healing) 
'( 
92 
'. FJgure 1: 'B,ipp~y\Forceps Model (Pentax, KW2430S) used in this study. 
, ' 
, ! 
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Figure 1 
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Figure 2: Examples of Endoscopie Visual Healing Scores Used for Biopsies 
Performed in the Nonglandular Portion of the Equine Stomach 
Examples of lesions scored 1 (A), scored 2 (B), scored 3 (C) and scored 4 (D). 
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Figure 2 
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Figure 3: Examples of .E:ndoscopic Visu al Healing Scores for Biopsies Performed in 
the Glandular ~ortion of the Equine Stomach 
Examples of lesions scored 1 (A), scored 2 (B), scored 3 (C) and scored 4 (D). 
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Figure 3 
Figure 4: Median Gastric Biopsy Lesion Healing Scores for the Margo Plicatus (MP, 
Squares), Fundus (F, Triangles) and Glandular Mucosa (GL, CircIes) 
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Figure 4 
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a: Scores for MP significantly greater than for F and GL at p = 0.005. b: Scores for MP 
significantly greater than for F and GL at p = 0.007. 
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Figure 5: Macroscopic Views (A and C) and Photomicrographs (B and D) of Equine 
Gastric Glandular Mucosa (A and B) and Squamous Mucosa (C and D) 
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Figure 5: 
D 
Ruler in macroscopic views is in millimetres. Bar in photomicrographs represents 
500 Ilm. 
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